Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Malignant Lymphoma

  Free Subscription


Articles published in Eur J Haematol

Retrieve available abstracts of 55 articles:
HTML format



Single Articles


    June 2022
  1. ABBASOV E, Metzner B, Muller TH, Casper J, et al
    Herpes Zoster prophylaxis with low-dose acyclovir in patients with malignant lymphoma and multiple myeloma treated with autologous stem cell transplantation (ASCT).
    Eur J Haematol. 2022 Jun 10. doi: 10.1111/ejh.13810.
    PubMed     Abstract available


    May 2022
  2. VODICKA P, Benesova K, Janikova A, Prochazka V, et al
    Polatuzumab vedotin plus bendamustine and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma in the real world.
    Eur J Haematol. 2022 May 3. doi: 10.1111/ejh.13784.
    PubMed     Abstract available


    April 2022

  3. Retracted: Bevacizumab synergises with the BCL 2 inhibitor venetoclax to effectively treat B-cell non-Hodgkin's lymphoma.
    Eur J Haematol. 2022 Apr 27. doi: 10.1111/ejh.13776.
    PubMed    


    March 2022
  4. PENICHOUX J, Rio J, Kammoun L, Vermeulin T, et al
    Retrospective analysis of the safety of peripherally inserted catheters versus implanted port catheters during first-line treatment for patients with diffuse large B-cell lymphoma.
    Eur J Haematol. 2022 Mar 13. doi: 10.1111/ejh.13767.
    PubMed     Abstract available


  5. EZE C, Friedrich I, Hadi I, Schmidt-Hegemann NS, et al
    Primary radiation therapy in stage I/II indolent orbital lymphoma - a comprehensive retrospective recurrence and toxicity analysis.
    Eur J Haematol. 2022 Mar 11. doi: 10.1111/ejh.13765.
    PubMed     Abstract available


    January 2022
  6. GRAEF CM, Godel P, Falderbaum P, Balke-Want H, et al
    Impact of timing and precision of histopathological diagnosis on outcomes of patients with Burkitt Lymphoma and High-Grade B-Cell Lymphoma.
    Eur J Haematol. 2022 Jan 28. doi: 10.1111/ejh.13747.
    PubMed     Abstract available


  7. CENCINI E, Mecacci B, Rocco M, Innocenti F, et al
    Pixantrone in patients with relapsed/refractory diffuse large b-cell lymphoma: A real-life, retrospective, multicenter trial on behalf of the "RTL" (Regional Tuscan Lymphoma Network).
    Eur J Haematol. 2022 Jan 20. doi: 10.1111/ejh.13745.
    PubMed     Abstract available


  8. FU H, Shen J, Zhou H, Zhang F, et al
    Mutation profiling of circulating tumor DNA identifies distinct mutation patterns in non-Hodgkin lymphoma.
    Eur J Haematol. 2022 Jan 7. doi: 10.1111/ejh.13736.
    PubMed     Abstract available


  9. BEYAR-KATZ O, Kikozashvili N, Bar On Y, Amit O, et al
    Characteristics and recognition of early infections in patients treated with commercial anti-CD19 CAR-T cells.
    Eur J Haematol. 2022;108:52-60.
    PubMed     Abstract available


    December 2021
  10. NOSAKA K, Crawford B, Yi J, Kuan W, et al
    A Systematic Review of Survival Outcomes for Relapsed or Refractory Adult T-Cell Leukemia-Lymphoma.
    Eur J Haematol. 2021 Dec 4. doi: 10.1111/ejh.13728.
    PubMed     Abstract available


  11. WEISSINGER SE, Zahn M, Marienfeld R, Tessmer C, et al
    Combination of two monoclonal antibodies with SOCS1 N- and C-terminal binding sites to address SOCS1 status in B cells and B-cell lymphoma.
    Eur J Haematol. 2021 Dec 1. doi: 10.1111/ejh.13730.
    PubMed     Abstract available


    November 2021
  12. CUNNINGHAM I, Sosa SS, Hamele-Bena D
    A single organ microenvironment and the common features of tumors of leukemia, lymphoma, and myeloma cells growing there. A literature review.
    Eur J Haematol. 2021 Nov 15. doi: 10.1111/ejh.13727.
    PubMed     Abstract available


  13. SMITH T, Cunningham-Rundles C
    Lymphoid malignancy in common variable immunodeficiency in a single-center cohort.
    Eur J Haematol. 2021;107:503-516.
    PubMed     Abstract available


    October 2021
  14. FREITAS AC, Carvalho IP, Esteves S, Salgado L, et al
    End of treatment FDG-PET in primary mediastinal B-cell lymphoma treated with R-chemotherapy: Prognostic indicator and implications for consolidation radiotherapy.
    Eur J Haematol. 2021 Oct 2. doi: 10.1111/ejh.13715.
    PubMed     Abstract available


  15. LACOMBE V, Nunes Gomes C, Robin JB, Thepot S, et al
    Risk of infection according to the gamma globulin level in the 100 days following allogeneic stem cell transplantations.
    Eur J Haematol. 2021;107:489-496.
    PubMed     Abstract available


    September 2021
  16. BRIAND M, Gerard S, Gauthier M, Garric M, et al
    Impact of therapeutic management and geriatric evaluation on patient of 80 years and older with diffuse large B-cell lymphoma on survival: a systematic review.
    Eur J Haematol. 2021 Sep 8. doi: 10.1111/ejh.13704.
    PubMed     Abstract available


  17. KUIJVENHOVEN MA, Wilhelm AJ, Meijer E, Janssen JJWM, et al
    TRough versus AUC Monitoring of cyclosporine: A randomized comparison of adverse drug reactions in adult allogeneic stem cell recipients (TRAM study).
    Eur J Haematol. 2021;107:364-369.
    PubMed     Abstract available


  18. VERLINDEN A, Schroyens WA, Gadisseur AP
    Clinical and microbiological impact of long-term discontinuation of fluoroquinolone prophylaxis in haematological patients with prolonged profound neutropenia.
    Eur J Haematol. 2021;107:377-379.
    PubMed    


  19. ATTMAN E, Syrjanen J, Lyytikainen O, Ollgren J, et al
    Healthcare-associated blood stream infections in hematological patients in Finland during the years 2006-2016.
    Eur J Haematol. 2021;107:311-317.
    PubMed     Abstract available


    July 2021
  20. METZNER B, Pott C, Muller TH, Casper J, et al
    Long-term outcome in patients with follicular lymphoma following high-dose therapy and autologous stem cell transplantation.
    Eur J Haematol. 2021 Jul 20. doi: 10.1111/ejh.13691.
    PubMed     Abstract available


  21. WIGHT J, Wai SH, Shen E, Lee ST, et al
    Predicting primary treatment failure using interim FDG-PET scanning in Diffuse large B-cell lymphoma.
    Eur J Haematol. 2021 Jul 8. doi: 10.1111/ejh.13684.
    PubMed     Abstract available


  22. WU X, Nowakowski KE, Abeykoon JP, Manske M, et al
    MCIR1: A Patient-Derived Mantle Cell Lymphoma Line for Discovering New Treatments for Ibrutinib Resistance.
    Eur J Haematol. 2021 Jul 2. doi: 10.1111/ejh.13682.
    PubMed     Abstract available


  23. MORTENSEN JB, Monrad I, Enemark MB, Ludvigsen M, et al
    Soluble programmed cell death protein 1 (sPD-1) and the soluble programmed cell death ligands 1 and 2 (sPD-L1 and sPD-L2) in lymphoid malignancies.
    Eur J Haematol. 2021;107:81-91.
    PubMed     Abstract available


  24. WEISSINGER SE, Zahn M, Marienfeld R, Tessmer C, et al
    A new reliable and highly specific monoclonal antibody to detect the C-terminal region of silencer of cytokine signaling 1.
    Eur J Haematol. 2021;107:74-80.
    PubMed     Abstract available


    May 2021
  25. RENAUD L, Bossard JB, Carpentier B, Terriou L, et al
    Treatment with temozolomide and ibrutinib in Recurrent/Refractory Primary (PCNSL) and Secondary CNS Lymphoma (SCNSL).
    Eur J Haematol. 2021 May 21. doi: 10.1111/ejh.13667.
    PubMed     Abstract available


  26. SHANMUGASUNDARAM K, Goyal S, Switchenko J, Calzada O, et al
    Intensive Induction Regimens after Deferring Initial Therapy for Mantle Cell Lymphoma Are Not Associated with Improved Survival.
    Eur J Haematol. 2021 May 11. doi: 10.1111/ejh.13649.
    PubMed     Abstract available


  27. SIEG N, Naendrup JH, Godel P, Balke-Want H, et al
    Treatment patterns and disease course of previously untreated Primary Central Nervous System Lymphoma - feasibility of MTX-based regimens in clinical routine.
    Eur J Haematol. 2021 May 7. doi: 10.1111/ejh.13639.
    PubMed     Abstract available


  28. HANSEN S, Alduaij W, Biggs CM, Belga S, et al
    Ruxolitinib as adjunctive therapy for secondary hemophagocytic lymphohistiocytosis: A case series.
    Eur J Haematol. 2021;106:654-661.
    PubMed     Abstract available


    April 2021
  29. YUDA S, Maeshima AM, Taniguchi H, Ito Y, et al
    Clinicopathological factors and tumor microenvironment markers predicting watch-and-wait discontinuation in 82 patients with follicular lymphoma.
    Eur J Haematol. 2021 Apr 27. doi: 10.1111/ejh.13637.
    PubMed     Abstract available


    March 2021
  30. OKABE M, Morishita T, Yasuda T, Sakaguchi H, et al
    Targeted deep next generation sequencing identifies potential somatic and germline variants for predisposition to familial Burkitt lymphoma.
    Eur J Haematol. 2021 Mar 27. doi: 10.1111/ejh.13629.
    PubMed     Abstract available


  31. MELODY M, Gandhi S, Rahman ZA, Diaz PL, et al
    Impact of Hypoalbuminemia on the Prognosis of Relapsed/Refractory B-Cell Lymphoma Treated with Axicabtagene Ciloleucel.
    Eur J Haematol. 2021 Mar 2. doi: 10.1111/ejh.13609.
    PubMed     Abstract available


    February 2021
  32. ZDUNIAK A, Mihailescu SD, Lequesne J, Lenain P, et al
    Outcomes after intensive care unit admission in newly diagnosed diffuse large B-cell lymphoma patients: a real-life study.
    Eur J Haematol. 2021 Feb 23. doi: 10.1111/ejh.13606.
    PubMed     Abstract available


  33. VACHON H, Mierzynska J, Taye M, Pe M, et al
    Reference values for the EORTC QLQ-C30 in patients with advanced stage Hodgkin Lymphoma and in Hodgkin Lymphoma survivors.
    Eur J Haematol. 2021 Feb 11. doi: 10.1111/ejh.13601.
    PubMed     Abstract available


    January 2021
  34. ABDAYEM P, Ibrahim N, El Dakdouki Y, Willekens C, et al
    Attenuated Cytarabine, Etoposide, Dexamethasone plus Rituximab (R-Mini-CYVE) Regimen for Patients with Relapsed or Refractory B-cell non-Hodgkin's Lymphoma not Eligible for Intensive Chemotherapy.
    Eur J Haematol. 2021 Jan 29. doi: 10.1111/ejh.13589.
    PubMed     Abstract available


  35. ROCHE P, Venton G, Berda-Haddad Y, Fritz S, et al
    Could Daratumumab induce the maturation of plasmablasts in Plasmablastic Lymphoma? Potential therapeutic applications.
    Eur J Haematol. 2021 Jan 20. doi: 10.1111/ejh.13584.
    PubMed     Abstract available


    December 2020
  36. VAN DE WYNGAERT Z, Coppo P, Cervera P, Fabiani B, et al
    Combination of brentuximab-vedotin and ifosfamide, carboplatin, etoposide (ICE) in relapsed/refractory peripheral T-cell lymphoma.
    Eur J Haematol. 2020 Dec 15. doi: 10.1111/ejh.13568.
    PubMed     Abstract available


  37. SEKINE M, Kameda T, Shide K, Maeda K, et al
    Higher average chemotherapy dose intensity improves prognosis in patients with aggressive adult T-cell leukemia/lymphoma.
    Eur J Haematol. 2020 Dec 10. doi: 10.1111/ejh.13565.
    PubMed     Abstract available


    November 2020
  38. PICARDI M, Giordano C, Della Pepa R, Cerchione C, et al
    Correspondence in reference to previously published manuscript: "Faouzi Djebbari et al. Efficacy and infection morbidity of front-line immuno-chemotherapy in follicular lymphoma. Eur J Haematol 2020; 105: 667-671."
    Eur J Haematol. 2020 Nov 30. doi: 10.1111/ejh.13558.
    PubMed     Abstract available


  39. MOZAS P, Sorigue M, Rivas-Delgado A, Rivero A, et al
    The interval between frontline treatment and the second relapse (PFS2) predicts survival from the second relapse in follicular lymphoma patients.
    Eur J Haematol. 2020 Nov 28. doi: 10.1111/ejh.13556.
    PubMed     Abstract available


  40. SANCHEZ-PINA JM, Rodriguez Rodriguez M, Castro Quismondo N, Gil Manso R, et al
    Clinical course and risk factors for mortality from COVID-19 in patients with haematological malignancies.
    Eur J Haematol. 2020;105:597-607.
    PubMed     Abstract available


    October 2020
  41. NOZAKI K, Maruyama D, Maeshima AM, Tajima K, et al
    The role of local radiotherapy following rituximab-containing chemotherapy in patients with transformed indolent B-cell lymphoma.
    Eur J Haematol. 2020 Oct 24. doi: 10.1111/ejh.13539.
    PubMed     Abstract available


  42. UCHIDA Y, Yoshimitsu M, Hachiman M, Kusano S, et al
    RLTPR Q575E: A novel recurrent gain-of-function mutation in patients with adult T-cell leukemia/lymphoma.
    Eur J Haematol. 2020 Oct 24. doi: 10.1111/ejh.13540.
    PubMed     Abstract available


  43. BELLMANN-WEILER R, Burkert F, Schwaiger T, Schmidt S, et al
    Janus-faced course of COVID-19 infection in patients with hematological malignancies.
    Eur J Haematol. 2020;105:502-504.
    PubMed    


    September 2020
  44. KADDU-MULINDWA D, Rosolowski M, Ziepert M, Regitz E, et al
    VEGFR2 and VEGFA polymorphism are not associated with an inferior prognosis in Caucasian patients with aggressive B-cell lymphoma.
    Eur J Haematol. 2020 Sep 30. doi: 10.1111/ejh.13526.
    PubMed     Abstract available


    August 2020
  45. SANTOPIETRO M, Kovalchuk S, Battistini R, Puccini B, et al
    Treatment and prognosis of primary pulmonary lymphoma: a long-term follow-up study.
    Eur J Haematol. 2020 Aug 11. doi: 10.1111/ejh.13507.
    PubMed     Abstract available


    July 2020
  46. DJEBBARI F, Kaji F, Stanton L, Lawrence MM, et al
    Efficacy and infection morbidity of frontline immuno-chemotherapy in follicular lymphoma.
    Eur J Haematol. 2020 Jul 15. doi: 10.1111/ejh.13486.
    PubMed     Abstract available


  47. POLLARI M, Pellinen T, Karjalainen-Lindsberg ML, Kellokumpu-Lehtinen PL, et al
    Adverse prognostic impact of regulatory T-cells in testicular diffuse large B-cell lymphoma.
    Eur J Haematol. 2020 Jul 6. doi: 10.1111/ejh.13484.
    PubMed     Abstract available


    June 2020
  48. SATAKE A, Konishi A, Azuma Y, Tsubokura Y, et al
    Clinical efficacy of mogamulizumab for relapsed/refractory aggressive adult T-cell leukemia/lymphoma: A retrospective analysis.
    Eur J Haematol. 2020 Jun 21. doi: 10.1111/ejh.13474.
    PubMed     Abstract available


  49. FACCHINELLI D, Sina S, Boninsegna E, Borin A, et al
    Primary Pancreatic Lymphoma: Clinical Presentation, Diagnosis, Treatment and Outcome.
    Eur J Haematol. 2020 Jun 16. doi: 10.1111/ejh.13468.
    PubMed     Abstract available


  50. MCILROY G, Barmayehvar B, Kamarajah SK, George L, et al
    Improved outcomes with allogeneic compared with autologous stem cell transplantation in aggressive T-cell lymphoma.
    Eur J Haematol. 2020 Jun 8. doi: 10.1111/ejh.13465.
    PubMed     Abstract available


    May 2020
  51. CHOU WC, Chang H, Wang PN, Kuo MC, et al
    Application of comprehensive geriatric assessment in predicting early mortality among elder patients with B-cell lymphoma receiving immunochemotherapy.
    Eur J Haematol. 2020 May 30. doi: 10.1111/ejh.13457.
    PubMed     Abstract available


  52. SANCHO JM, Navarro B, Soler Campos JA, de Oteyza JP, et al
    Efficacy and safety of pixantrone for the treatment of multiply relapsed or refractory aggressive non-Hodgkin B-cell lymphomas.
    Eur J Haematol. 2020;104:499-508.
    PubMed     Abstract available


    April 2020
  53. LACOUT C, Orvain C, Seegers V, De Vries M, et al
    R-DHA-oxaliplatin (R-DHAOx) versus R-DHA-cisplatin (R-DHAP) regimen in B-cell lymphoma treatment.
    Eur J Haematol. 2020 Apr 17. doi: 10.1111/ejh.13429.
    PubMed     Abstract available


  54. KARI EJM, Kuusisto MEL, Honkavaara P, Hakalahti A, et al
    Thioredoxin-1 as a biological predictive marker for selecting diffuse large B-cell lymphoma patients for etoposide-containing treatment.
    Eur J Haematol. 2020 Apr 5. doi: 10.1111/ejh.13419.
    PubMed     Abstract available


    March 2020
  55. WAGNER SM, Melchardt T, Egle A, Magnes T, et al
    Treatment with brentuximab vedotin plus bendamustine in unselected patients with CD30-positive aggressive lymphomas.
    Eur J Haematol. 2020;104:251-258.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Lymphoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: